Opinion|Videos|January 20, 2025
University of Kansas Medical Center Insights: CAR T Referral Process
Panelists discuss how the chimeric antigen receptor T-cell referral pathway progresses from initial community physician contact through patient evaluation and final selection, highlighting the key steps and considerations in the institutional workflow process.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Walk us through the typical chimeric antigen receptor T-cell referral process at your institution, from the initial community physician outreach to the patient evaluation and selection.
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
FDA Clears TriNav Advance for Expanded Liver Embolization Access
4
Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
5